Related Experiment Video
Updated: Sep 12, 2025

Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach
Published on: December 1, 2011
Tecovirimat at a crossroads: What the PALM007 trial tells us
Olivier Segeral1, Yazdan Yazdanpanah2, Alexandra Calmy1
1HIV Unit, Division of Infectious Diseases, University Hospital Geneva, University of Geneva, Geneva, Switzerland.
Abstract:
The double-blind, randomized, placebo-controlled PALM007 trial did not report any significant differences between placebo and tecovirimat regarding the time-to-lesion resolution or the virological clearance for the treatment of clade I Mpox virus infection in the Democratic Republic of Congo.1 We discuss how these results compare with other clinical trials and what lessons can be drawn for future therapeutics strategies.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Antimicrobial Effectiveness
Preclinical Development: Overview

